Why NeoGenomics Shares Are Trading Higher Today
NeoGenomics Inc (NASDAQ:NEO) reported Q4 revenues of $138.71 million, +10.3% Y/Y beating the consensus of $129.97 million but aligned with…
Evolent Health Q4 Top-Line Beats Expectation, Analyst Points To Visible Growth Outlook
Evolent Health Inc (NYSE:EVH) reported Q4 adjusted EPS of $0.10, missing the consensus of $0.16, compared to $0.08 a year…
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Blueprint Medicines Corporation (NASDAQ:BPMC) will regain global commercialization and development rights to Gavreto (pralsetinib), excluding Greater China, following a…
Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit
Sangamo Therapeutics Inc (NASDAQ:SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR…
4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study
4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced updated interim safety and efficacy data from the two 4D-310 INGLAXA Phase 1/2 trials for…
Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study
Denali Therapeutics Inc (NASDAQ:DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 in children with…
Tandem Diabetes Care Shares Fell Post Q4 Results; Guides Within Estimates
Tandem Diabetes Care Inc (NASDAQ:TNDM) reported Q4 FY22 sales of $220.50 million, missing the consensus of $221.83 million. The automated…
GSK/Pfizer-Backed ViiV Healthcare’s HIV Treatment At Par With Gilead’s: Study Shows
ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…
Analyst Says This MedTech Giant Stock Offers ‘Too Much Optionality,’ Upgrades Rating
Raymond James upgraded Masimo Corporation (NASDAQ:MASI) from Market Perform To Outperform with a price target of $187 and says that no other company…
Analyst Sees Attractive Entry Opportunity After BioCryst’s Pipeline Setback
Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a setback on the early-stage BCX10013 study. The company…